NASDAQ:CRVO CervoMed Q3 2026 Earnings Results & Report $1.35 -0.08 (-5.52%) As of 02:15 PM Eastern This is a fair market value price provided by Massive. Learn more. CervoMed beat analyst earnings expectations in its Q3 2026 results, released November 9, 2026. The company reported EPS of -$0.39 versus the -$0.4750 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 9, 2026TimeBefore Market OpensConference Call DateNovember 6, 2026Conference Call7:00 AM ET CervoMed EPS ResultsActual EPS-$0.39Consensus EPS -$0.4750Beat/MissBeat by +$0.0850One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersCervoMed Revenue ResultsActual RevenueN/AExpected Revenue$83 thousandBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) CervoMed Q3 2026 Earnings FAQ Did CervoMed beat earnings estimates for Q3 2026? CervoMed (NASDAQ:CRVO) reported earnings of -$0.39 per share for Q3 2026, beating the consensus estimate of -$0.4750. The report was announced on Monday, November 9, 2026. CervoMed Earnings HeadlinesCervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatesNovember 9 at 7:30 AM | globenewswire.comCervoMed (CRVO) Projected to Post Quarterly Earnings on ThursdayNovember 5, 2026 | americanbankingnews.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 10 at 1:00 AM | Behind the Markets (Ad)CervoMed Inc. (NASDAQ:CRVO) Stock Has Consensus Price Target of $21.00 According to AnalystsNovember 2, 2026 | americanbankingnews.comCervoMed Reports Published RewinD-LB and Cells Studies Supporting Neflamapimod’s Potential in Dementia with Lewy BodiesOctober 29, 2026 | quiverquant.comQAnalysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), CervoMed (CRVO)October 20, 2026 | theglobeandmail.comSee More CervoMed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CervoMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CervoMed and other key companies, straight to your email. Email Address About CervoMedCervoMed (NASDAQ:CRVO) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company’s lead investigational product is neflamapimod, an orally administered, brain-penetrant small-molecule inhibitor of p38 alpha, an enzyme believed to play a role in neuroinflammation and cognitive decline. CervoMed is primarily evaluating neflamapimod as a potential treatment for dementia with Lewy bodies, a progressive neurological disorder associated with cognitive impairment, fluctuations in attention, visual hallucinations and movement symptoms. The company has also studied the compound in other forms of dementia, including Alzheimer’s disease, and continues to use clinical research to assess its potential effects on cognition and other disease-related symptoms. The company’s activities are centered on drug development, clinical trials and related research rather than commercialized products. CervoMed’s development programs are conducted through collaborations with clinical research organizations, investigators and medical institutions, with studies focused primarily on patients in the United States and other regions where clinical trials are authorized. The company is headquartered in the United States and trades on the Nasdaq Capital Market under the symbol CRVO.View CervoMed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
